A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
36
Participants
Timeline
Start Date
May 8, 2019
Primary Completion Date
August 4, 2019
Study Completion Date
August 4, 2019
Conditions
Healthy
Interventions
DRUG
Tucatinib
Administered via oral tablet
Trial Locations (1)
91206
PAREXEL International, Early Phase Clinical Unit - Los Angeles, Glendale
All Listed Sponsors
lead
Seagen Inc.
INDUSTRY
NCT03914755 - A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter